Ascent Strategic Communications

Mighty Therapeutics Initiates IND-Enabling Studies of MYTX-255: a Mitochondrial-Targeted Therapeutic Candidate

New data presented in long-chain fatty acid oxidation disorders at INFORM 2026 support development of Company's third mitochondrial-targeted candidate

American Shoulder and Elbow Surgeons: New Members Announced

CHARLOTTE, N.C. – September 1, 2026 – In August 2026, Edward C. Brown III, MD, was elected to join the ranks of the American Shoulder and Elbow Surgeons (ASES) as a General Member. General membership in ASES is a privilege and an honor only awarded to young orthopaedic s...

1 September 2026

Free Family Caregiver Series Returns to the Lowcountry To Educate, Support, and Uplift

Six events held across four counties will feature national guest speakers, caregiver panels, and a virtual advance care planning workshop

25 August 2026

Statement from James Dismond, CEO of MiraSol Health, on South Carolina’s Investment in Home- and Community-Based Care

BLUFFTON, S.C.-- Aug. 18, 2026 -- “South Carolina’s 2026-2027 budget sends a strong message: The future of health care is moving into the home. While much of the conversation has focused on the dollars invested, the bigger story is the state’s continued commitment to hel...

18 August 2026

Mighty Therapeutics and University of Washington Team Named Milestone 2 Awardee in $101M XPRIZE Healthspan Competition

NEEDHAM, Mass. — August 11, 2026 — Mighty Therapeutics (the “Company” or “Mighty”), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced that a joint ...

AvenueWest Global Named to Inc. 5000 List for Eighth Time

Company Recognized for 167% Three-Year Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses

11 August 2026

Waiver Extension Doubles Down on a Failed Experiment at the Expense of American MaritimeJobs

NEW ORLEANS — Aug. 10, 2026 — The Offshore Marine Service Association (OMSA) is responding to the Trump administration's decision to extend the current Jones Act waiver despite clear evidence it has failed to lower fuel prices while continuing to undermine American marit...

10 August 2026

Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026

- FDA confirmed the resubmission is a complete, Class II response to the Aug. 27, 2025 CRL.

28 July 2026

New Housing Law Could Open Doors for Homebuyers and Individual Real Estate Investors

Global Real Estate Veteran Angela Healy says increasing housing supply remains critical to affordability and workforce growth

28 July 2026

OMSA Calls on Congress to End Regulatory Disparities Hurting U.S.-Flagged Vessels

Restated Marine Safety Mission and New Civilian Secretary of the Coast Guard proposed as solutions

23 July 2026